In 1949, a small number of patients with anemia and predisposition to acute myeloid leukemia (AML) were referred to as "pre-leukemic anemia [1] ." These patients were to be diagnosed as myelodysplastic syndromes (MDS), based on the present concept. The term "pre-leukemia" since then has been used to imply MDS in most documents, while chronic phases of chronic myeloid leukemia (CML) and myeloproliferative neoplasms (MPN) have also been characterized as pre-leukemia in more limited contexts.
A change has been brought by the introduction of second-generation sequencing technology. In 2012, Jan, et al. reported the presence of clonal hematopoietic stem cells (HSCs), having mutations in selected genes in the bone marrow of de novo AML patients achieving a complete remission [2] . Additional evidence conveyed by Shlush, et al., who used a xenogeneic transplant model, further indicated that de novo AML often has a pre-leukemic phase without any clinical manifestations [3] . Shlush reviews this tale. He further discusses currently expanding concept interconnecting aging, clonal hematopoiesis, and preleukemia. 
